​

GridAI Technologies Stock (NASDAQ:GRDX)

FinancialsChart
GridAI Technologies by TradingView

Previous Close

$2.95

52W Range

$0.97 - $5.84

50D Avg

$3.24

200D Avg

$2.69

Market Cap

$10.29M

Avg Vol (3M)

$143.12K

Beta

1.13

Div Yield

-

GRDX Company Profile

GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Oct 11, 2016

Website

GRDX Performance

GRDX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-15.62M$-15.77M$-12.68M
Net Income$-18.06M$-15.79M$-14.63M
EBITDA$-15.57M$-15.74M$-14.58M
Basic EPS$-3.88$-46.96$-407.37
Diluted EPS$-5.33$-46.96$-407.37

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
ASBPAspire Biopharma Holdings, Inc.
PCSAProcessa Pharmaceuticals, Inc.
ATHAAthira Pharma, Inc.
CRISCuris, Inc.
BCTXBriaCell Therapeutics Corp.
LPTXLeap Therapeutics, Inc.
ALLRAllarity Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
CINGCingulate Inc.
PALIPalisade Bio, Inc.